Dexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 Diabetes
Dexcom, a leader in continuous glucose monitoring (CGM) technology, announced that its Dexcom ONE sensor will now be reimbursed for around 100,000 Type 2 diabetes (T2D) patients in France. This decision allows individuals over 2 years old, on non-intensified insulin therapy, and with HbA1c ≥ 8% to access this technology. France becomes the first European country to offer full national reimbursement for CGM for T2D patients. This follows similar moves in the USA and New Zealand. Further, Germany's KKH health insurance provider has also started reimbursing Dexcom sensors for T2D patients. Dexcom's survey in the UK revealed that 63% of T2D patients face challenges in managing their condition, and 83% are open to using CGM technology. With T2D diagnoses rising globally, the adoption of CGM technology like Dexcom's could improve management and reduce healthcare costs.
- France approves national reimbursement for Dexcom ONE for 100,000 T2D patients.
- Dexcom secures reimbursement in Germany through health insurance provider KKH.
- French reimbursement decision marks Dexcom's first full national CGM coverage in Europe.
- Survey shows 83% of UK T2D patients are open to using CGM technology.
- Dexcom claims CGM usage can improve T2D management and reduce healthcare costs.
- Only 39% of T2D patients in the UK survey have used CGM technology.
- Survey indicates 63% of UK T2D patients struggle with diabetes management.
Insights
Dexcom's new reimbursement approval in France is a notable development that could positively influence the company's revenue streams and market share. The reimbursement will likely boost
From a financial perspective, this increases predictability and stability in revenue from the French market. More importantly, it could lead to a cascading effect, prompting other European nations to follow France’s lead. The impact on Dexcom's financials can be both short-term, with a boost in immediate sales and long-term, by establishing a more consistent revenue stream.
Investors should note that Dexcom’s earnings could see a significant uptick. However, one should consider the investment required to supply and support this expanded user base. Initially, the costs might slightly suppress margins, but the long-term benefits far outweigh these short-term expenses.
The French government’s decision to reimburse Dexcom’s CGM technology for Type 2 diabetes patients indicates a growing shift toward technology-driven diabetes management. Continuous glucose monitoring (CGM) systems have been shown to improve glycaemic control significantly compared to traditional self-monitoring blood glucose methods. This can reduce complications such as cardiovascular diseases, thereby potentially lowering healthcare costs long-term.
For healthcare providers, this development showcases a broader acceptance of CGM as a standard care component for Type 2 diabetes, especially in cases where glycaemic control is inadequate. This creates a precedent for healthcare systems globally to reevaluate their diabetes management protocols. In the short term, this may lead to an increase in demand for educational resources and training for both patients and healthcare providers.
The announcement also aligns with recent studies that underscore the cost-effectiveness of CGM technologies for managing diabetes. Such evidence further solidifies the case for widespread adoption and reimbursement, reducing the financial burden on both patients and healthcare systems.
This reimbursement decision in France is a important stepping stone for Dexcom as it expands its European market penetration. By securing national reimbursement, Dexcom can further solidify its position as a market leader in CGM technology. This will likely create a competitive advantage over other players in the market, particularly those still awaiting similar approvals.
For investors, the broader market implications are worth considering. The news could prompt increased interest and investment in CGM and other diabetes management technologies. As governments and healthcare providers increasingly recognize the cost benefits and improved patient outcomes associated with these technologies, the market for CGM is likely to grow substantially.
In the short term, investors could expect a positive sentiment around Dexcom’s stock, driven by the potential for increased sales and market presence. Long-term, the expanding market and growing adoption of CGM technology could lead to substantial returns on investment.
The French reimbursement news is part of worldwide growing awareness by governments and healthcare providers of the impact that rising diagnoses of T2D have on both national healthcare services and those living with the condition. Governments and healthcare providers are increasingly looking to technology, such as Dexcom CGM, for a solution, as studies demonstrate both the health benefits of CGM for T2D and the potential cost savings for health services1-5. Dexcom also recently secured reimbursement of its sensors in
“The decision by the French government to offer national reimbursement for Dexcom CGM to those treating their Type 2 diabetes with basal insulin injections is a significant step forward in both the treatment and understanding of Type 2 diabetes on both an individual and societal level,” said Alex Moussa, Senior Vice President and General Manager of Dexcom EMEA & LATAM. “We will continue to advocate for widening access to our life-changing technology for those living with Type 2 diabetes. The science and economics are clear: our technology can significantly improve the management of Type 2 diabetes, positively impact the lives of those living with the condition, and lead to cost savings for healthcare services.”
The management of T2D is a hot topic around the world as diagnoses of the condition continue to steadily grow, with Western European countries seeing some of the fastest growth rates*6. The impact on the lives of those living with the condition is also becoming clearer. A recent, first-of-its-kind survey by Dexcom of those living with T2D in the
However, while the use of CGM technology to help manage T2D is on the rise, it remains an underutilised technology. The same survey showed that although those living with the condition were keen to turn to technology for a solution, prescribing CGM for T2D is not standard practice among healthcare professionals. Across the spectrum of T2D users, only
*2017 6059 cases of T2 diabetes per 100,000 people, expected to reach 7079 per 100,000 by 2030.
1 Alshannaq H et al Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in
Category: IR
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604408592/en/
Gemma McDonald
+44 (0) 7552 368398
gemma.mcdonald@dexcom.com
Source: DexCom, Inc.
FAQ
What did Dexcom announce regarding access to Dexcom ONE?
Which country in Europe first offered full national reimbursement for Dexcom CGM technology for T2D patients?
What is the significance of the reimbursement decision by the French government?
How many T2D patients in the UK survey expressed willingness to use CGM technology?
What percentage of T2D patients in the UK survey had used CGM technology?
